Ketamine against bipolar disorder new medication against mental illnesses from October 2006 until June 2009, 18 participants with bipolar depression that had not responded to lithium or valproate medications received an intravenous infusion of ketamine or a placebo in two days of two-week difference test. The order of tea was assigned randomly. The participants were evaluated using a rating scale of depression before each injection and then 40, 80, 120 and 230 and one minute, then two, three, seven, 10 and 14 days. Within 40 minutes, those who received ketamine experienced a significant improvement in depressive symptoms compared with those taking placebo, an improvement that the mayor was on the second day and remained significant across three days. Sometime during the course of the trial, 71 per cent of the participants responded to ketamine and 6 per cent responded to placebo. These findings are particularly significant because a proportion substantial participants in the study had prescribed complex regimes of polypharmacy in the past with the substantial treatment failures, write the authors. The average number of trials with antidepressant last seven years, and more than 55 percent of the participants failed to respond to electroconvulsive therapy. The number of victims of this prolonged and refractory disease subjects was evident, in which two thirds of the participants were on psychiatric disability and almost all were unemployed. More information on bipolar disorder.